Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN.  Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.

Nigel obtained his BSc in Microbiology and Genetics from University College London (UCL) in 1990 and an MSc in Applied Molecular Biology of Infectious Diseases (1992), PhD in Molecular Parasitology (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine (LSHTM). After his PhD, he returned to UCL as a post-doctoral scientist in the Division of Infection and Immunity. In 2009 Nigel was elected as a member of the highly prestigious Medical Research Club and set up his own research group at the University of Kent. He is currently Chair and Professor in Molecular Virology, Director of the Viral Pseudotype Unit (VPU) and Director of Research and Innovation. Nigel is a Fellow of the Royal Society of Biology (FRSB), Senior Associate Member of the Royal Society of Medicine (RSM), Member of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV), the Microbiology Society and the European Society for Virology (ESV). Nigel acts as external consultant for VisMederi (Italy) and RQbio (UK). He has published over 200 articles with an h-index of 53, >14k citations.

Ruben Rizzi, physician by training, SVP of Global Regulatory Affairs at BioNTech. I joined the company in December 2019 just before the pandemic, and I have been the global regulatory lead for BioNTech for our COVID-19 development. Currently, I am still supporting the lifecycle of our COVID-19 vaccine, and I am co-leading the Global Regulatory Affairs department at BioNTech and working closely with the teams that are responsible for the development of BioNTech´s pipeline, post-approval activities and labelling

Professor Adrian V. S. Hill FRS is the Director and Founder of the Jenner Institute, and Mital Professor of Vaccinology at Oxford University. He is a passionate believer in the power of molecular medicine to address many of the most egregious health care inequities globally. His group have been leaders in the development of adenoviral and other vaccines against infectious diseases and he has tested these in extensively in over eighty clinical trials in Africa and Europe. In partnership with the Serum Institute of India and AstraZeneca the Jenner Institute developed rapidly a ChAdOx1 vector-based SARS-CoV-2 vaccine which saved an estimated 6.2 million lives in 2021 alone.

His lab also designed a newly licensed high efficacy malaria vaccine, R21/Matrix-MTM, which has recently shown unprecedented high efficacy in a phase III trial in four African countries, again in partnership with the Serum Institute of India and also Novavax Inc. This vaccine promises to make a major impact on reducing the 500,000 childhood deaths from malaria each year. In 2021 he was elected a Fellow of the Royal Society and is a Knight Commander of the Order of the British Empire (KBE).

Melanie Saville, MBBS, is PATH’s Chief Scientific Officer. She leads PATH’s product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics.

Dr. Saville is a distinguished physician specializing in virology with more than two decades of experience developing and licensing vaccines for global use. Her contributions over the past 20 years have included the development of vaccines for seasonal and pandemic influenza, as well as pediatric combinations and vaccines against rabies, Japanese encephalitis, dengue, Ebola, and SARS-CoV-2.

Before joining PATH, Dr. Saville worked with the Coalition for Epidemic Preparedness Innovations (CEPI), where she served as the Executive Director of Vaccine Research and Development, leading technical teams supporting vaccine development. She also served as the R&D and manufacturing workstream leader for COVAX, part of a global collaboration to speed development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

Dr. Saville holds a medical degree, a master’s degree in medical virology, and a Bachelor of Science in molecular biology from University College, London.

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General). China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).

Dr. Hun Kim is the President of Global Business at SK Bioscience. His role is to oversee the company's product and platform portfolio in a comprehensive perspective from R&D to commercialization through global alliance and external innovation.

Dr. Hun Kim started his biopharmaceutical career in 1992 as a researcher at Green Cross Corporation, In 2000, he moved on to Berna Biotech, a part of Crucell at present. In 2008, he joined SK Chemicals,the parent company of SK Bioscience, and lead the company's expansion in vaccine R&D, Quality and manufacturing capabilities.

Under his oversight, the company developed and received approval for cell culture-based influenza vaccines (SKYCellflu/SKYCellflu Quadrivalent), varicella/herpes zoster vaccines (SKYVaricella/SKYZoster),and Pneumococcal Conjugation Vaccines. During the Pandemic, it successfully manufactured and supplied COVID-19 vaccines developed by AstraZeneca and NovaVax. With support from CEPI and BMGF, SK Bioscience also developed its own COVID-19 vaccine (SKYCovione), which became the first domestically developed COVID-19 vaccine to be approved in Korea.

Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant activity in late 1990s. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease. He served the president of Korean Vaccine Society (KVS) from 2013 to 2015. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of November 2023, he has more than 170 papers published in peer-reviewed journals and named as an inventor on 40 patents.

Prof. Ken J. Ishii, M.D., Ph.D., currently Director for Int. Vaccine Design Center, The Institute of Medical Science, the University of Tokyo, has 27 years of experience in Vaccine R&D since 1998 including 7 years as a IND reviewer at US Food and Drug Administration (FDA), 15 years as a basic immunologist at Osaka University, 9 years as a vaccine adjuvant expert at National Institute (NIBIOHN), 2 years as managing director at AMED (medical funding agency), as well as Advisor for PMDA (regulatory agency), GHIT (global fund) and CEPI. He has contributed to basic research on infectious diseases and immunology, resulted in numerous books and over 250 periodical publications and 35,000 citations with H-index 84 as well as over 50 patents related to vaccine and adjuvant, and to regulation of many vaccines and guidelines for vaccine preclinical and clinical trials in Japan and US.

Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.

Dr. Tan is responsible for drug discovery, preclinical development, translation research and external collaboration in China. Dr. Tan got his Ph.D. in Molecular Medicine from UT Health Science Center San Antonio and received his Postdoctoral training with Dr. Michael Karin at UC San Diego. Dr. Tan worked in Pfizer and Novartis for 9 years, specialized in drug discovery and translational research, bridging preclinical research to early clinical trials. Dr. Tan worked at Biosion Biotech and Coherent Biopharma before he joined Clover. Dr. Tan was selected as Jiangsu Innovation and Entrepreneur Talent and Suzhou Innovation and Entrepreneur Leading Talent.

Meng LI has been leading the International business team of CNBG since 2013, oversees CNBG’s international cooperation and registration activities. She also serves on the board of CNBG-Virogen, and the board of Emerging Biopharmaceuticals Manufacturers Network (EBPMN). During her 19 year experiences in biological industry, she established extensive networks with academia, NGOs, enterprises internationally, and successfully completed a number of landmark projects. Including the bOPV capacity expansion and prequalification program with BMGF (received over 23Million USD financial supports from BMGF, prequalified by WHO in 2019), establishment of CNBG’s first JV with foreign enterprise, the first overseas acquisition by CNBG, roll-out of the Covid-19 vaccine PhIII trials in 6 countries and its registration in over 100 countries. Meng Li has successfully signed a number of in-license, research cooperation, commercialization and industrialization projects with NIH, Oxford, France Institut Pasteur, PATH, IVI, biotech companies and developing country manufacturers. She worked as temporary advisor to WHO inspectorate during WHO’s first inspection to China NMPA in 2010, and was elected as the executive committee member of DCVMN from 2014-2016.

Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

Professor Linqi Zhang is the Director of the Comprehensive AIDS Research Center at Tsinghua University. Prof. Zhang's research focuses on HIV-1 pathogenesis and vaccine development, and has recently expanded to the field of emerging and re-emerging human viral pathogens such as SARS-CoV-1/2 and MERS-CoV. Using cutting-edge antibody and combinatorial antigen library techniques, Prof. Zhang’s research aims to characterize protective antibody immunity in infected humans and rational design of effective vaccines and therapies against the viral infection. Professor Zhang is the recipient of the National Outstanding Young Scientist Award, privileged Changjiang Professorship, and Bayer and Vanke Chair professor. He has published extensively and is among the most cited Chinese researchers in the field of microbiology and immunology. Professor Zhang has also served as a member of national expert and advisory board to the Chinese government and several international organizations on HIV/AIDS and infectious diseases,and was recently elected as a Foreign Fellow of the African Academy of Sciences.

Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.

Dr. Shibo Jiang is a Professor at the Shanghai Institute of Infectious Disease and Biosecurity of Fudan University, Shanghai, China. His main research interest is the development of antiviral drugs and vaccines. He has published 572 papers (total IF: 7,662, average IF: 13.4) in SCI journals such as Cell (x3), Nature (x2), Science (x2), Lancet (x4), CNS’ sister journals (x71), with total 45,327 citations and an h-index of 105. He has applied for 104 patents, 54 of which were issued, and 11 of them were licensed out with 3 classes of innovative drugs and medical products used in clinics.

Chris Netherton leads the African Swine Fever Vaccinology group and has been investigating different aspects of the life cycle of African swine fever virus (ASFV) for over twenty-five years. His studies on ASFV have encompassed analysis of individual viral proteins right through to herd transmission experiments. Chris’ earlier work on ASFV focussed on intracellular virus-host interactions with a strong emphasis on cell-biology.

The principal goal of the research carried out within the ASF Vaccinology group is to support the development of effective vaccines against this devastating disease of domestic pigs. We have identified a pool of eight ASFV genes that prevent severe disease in domestic pigs and aim to improve the protective efficacy of this combination, by characterising immune correlates of protection, identifying additional protective antigens and exploring different vaccine platforms. We are also sequencing Pirbright's reference collection of ASFV isolates to improve our understanding of the genetic diversity of this complex virus and help guide the development of cross-protective vaccines.

Graduated from Peking University School of Medicine, and National School of Development at Peking University, Jeffrey Zhang has deep insights in the fields of vaccines, while having extensive experience in business management, strategy and investment. He has successively served as the head of Pfizer’s New Business Development in China, General Manager of Emerging Business Department of GSK China/Vice President of Emerging Market Strategy, as well as the Vice President of Strategy of WuXi/Vice President of WuXi Vaccine Business.

Baik-Lin Seong, PhD, is a Distinguished Professor of Yonsei University College of Medicine, and Director General of Vaccine Innovative Technology ALliance (VITAL)-Korea. He received B.S. from Seoul National University (1977), M.S. from KAIST (1979), PhD from MIT (1988). He worked as postdoctoral scientist at the University of Oxford (1988-1992).

He served as a member of the Presidential Advisory Council of Science & Technology of Korean Government (2021-2022) and the Scientific Advisory Board of International Vaccine Institute (IVI) (2018-2022). He chaired the COVID-19 Vaccine Pan-Government Strategic Plan of the Korean Government (2020-2023).

With a view to ensure equitable access of effective vaccines to LMICs, he works on developing a low-cost production platform of VLP/nanoparticle vaccines against RSV, norovirus, nipah, universal influenza vaccine, and flavivirus vaccines including Japanese Encephalitis, Zika, and West Nile viruses.

Dr Robbert van der Most obtained his cum laude PhD in 1994 at Leiden University (Netherlands) on the topic of coronavirus molecular biology. He then conducted postdoctoral work on the immunology of chronic viral infection with Dr Rafi Ahmed(UCLA, Eiory University, USA) and flavivirus molecular biology with Dr Jim Strauss (Caltech, USA). Upon return to the Netherlands he worked on RSV vaccine immunology, focusing on the mechanisms of vaccine-enhanced disease. In 2004, he joined Dr Bruce Robinson's team at the University of Western Australia to study immune oncology and the immune-modifying effects of chemotherapy. In 2008, he joined GSK Vaccines in Belgium, in roles of increasing responsiblility, leadingTranslational Science, After a brief period at CEPl, he joined BioNTech as Vice-President Translational Science in 2022, leading a team of experts in the infectious disease portfolio, in 2024 he started his own consultancy business, aiming to provide scjentific and development advice to biotech and pharma companies, as well as not-for-profit organizations.

Jingxin Li, PhD, Professor, is working at Jiangsu Provincial Center for Disease Control and Prevention. Her research is focused on vaccine clinical evaluation and immunization strategy. She has participated in a lot of epidemiology investigations and a series of clinical trials of novel vaccines, including Enterovirus type 71 vaccine, recombinant human Ad5 vectored Ebola vaccine, and Covid-19 vaccines. She has got National Natural Science Outstanding Youth Founds and Jiangsu Provincial Natural Science Funds for Distinguished youths, and hosted or participated in seven National Natural Science Founds or National Science and Technology Major Projects. She has published over 25 articles in medical journals on vaccine clinical studies, including Nature Med, Lancet Respir Med, Lancet Glob Health, etc.

Prof. Yuelong Shu

Director, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College. He is a member of the Chinese Academy of Medical Sciences and a Fellow of the American Academy of Microbiology. He was selected as the first batch of ‘National Science and Technology Innovation Leader’and‘2014 Top Ten Scientific and Technological Innovators’, and is the winner of National Science Fund for Distinguished Young Scholars and the China Youth Science and Technology Award. He has been honored with the National Science and Technology Progress Grand Prize, First Prize, Second Prize, the National Medical and Health System Advanced Individual, the National Innovation Award, the Public Health and Preventive Medicine Development Contribution Award, etc. He is currently the Chairman of the Branch of Medical Virology of the Chinese Medical Association and the Chairman of the Asia-Pacific Alliance for the Control of Influenza (APACI). He was the founding dean of the School of Public Health of Sun Yat-sen University (Shenzhen), the editor-in-chief of the Chinese Journal of Virology, the deputy director of the Institute of Viral Diseases of the Chinese Center for Disease Control and Prevention (CDC), the director of the National Influenza Center, and the director of the WHO Collaborating Center for Reference and Research on Influenza.

Shu has long focused on influenza prevention and control research, and has made outstanding achievements in the discovery of new viruses, the development of detection reagents, and the pathogenesis of infection. Through the systematic establishment of new influenza detection and surveillance technology, it was found for the first time in the world that a variety of new avian influenza viruses such as H7N9, H5N6 and H10N8 can lead to human infection and death; The first successful development of pandemic H1N1 2019 and H7N9 avian influenza detection reagent; The origin, evolution and infection mechanism of H7N9 and other avian influenza viruses were clarified, which provided key scientific and technological support for the successful prevention and control of the epidemic in China. He has published nearly 200 papers in Science, Nature, NEJM, Lancet and other academic journals as a corresponding author. The research results were selected as one of the ‘China’s 100 most influential international academic papers in 2013’and ‘2013 Top Ten Scientific Advances in China’.

Dr. Linfa Wang is a professor of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School, and the inaugural executive director of PREPARE, Ministry of Health, Singapore. He is an international leader in the field of emerging zoonotic viruses and virus-host interaction. In response to the COVID-19 pandemic, he has served and is serving on multiple WHO committees for COVID-19, including the WHO IHR Emergency Committee. Prof. Wang has more than 500 scientific publications. He was the Editor-in-Chief for the Virology Journal from 2112-2022. Prof. Wang was elected to the Australian Academy of Technological Sciences and Engineering in 2010, the American Academy of Microbiology in 2021 and the Australian Academy of Sciences in 2023. He received the Singapore President Science Award in 2021

曹云龙，北京大学生物医学前沿创新中心（BIOPIC）研究员、助理教授，北大-清华生命科学联合中心研究员，北京昌平实验室领衔科学家，国家优秀青年科学基金获得者。2014年毕业于浙江大学竺可桢学院物理学专业，2019年获得哈佛大学化学博士学位。在新冠疫情期间，他围绕新冠病毒B细胞免疫应答、特异性抗体的结构与功能等开展了系统性研究，其中新冠中和抗体药物研制、新冠体液免疫响应特征和新冠突变免疫逃逸机制的创新性研究结果为抗击疫情做出了突出贡献。以第一作者、通讯作者在Nature、Cell、The Lancet Infectious Diseases、Cell Host & Microbe等期刊上发表多篇相关研究文章。相关研究成果获评2022年度“中国科学十大进展”、2022年度“中国生命科学十大进展”。其本人受邀作为WHO新冠疫苗成分技术咨询小组（TAG-CO-VAC）成员、国际流行病防范创新联盟（CEPI）科学顾问，获评2022年度北京市杰出青年中关村奖、《麻省理工科技评论》中国区“35岁以下科技创新35人”、2022年度Nature十大人物，获得国家优秀青年科学基金资助。

Dr. Dan Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. He is currently the William Bosworth Castle Professor of Medicine at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, a member of the Ragon Institute of MGH, MIT, and Harvard, and part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery.  His laboratory focuses on studying the immunology and pathogenesis of viral infections and developing novel vaccine and treatment strategies.  His group has led the development of vaccine candidates for multiple pathogens of global significance, including HIV, Zika virus, tuberculosis, and most recently SARS-CoV-2.  His work contributed to the development of the Johnson & Johnson COVID-19 vaccine and the evaluation of multiple COVID-19 vaccines and monoclonal antibody therapeutics.  He was elected to the National Academy of Medicine in 2020 and received the King Faisal Prize in Medicine in 2023.

Dr. SeyedReza Banihashemi is the Head of Immunology Department and an Assistant Professor at Razi Vaccine and Serum Research Institute in Karaj, Iran. He holds a Ph.D. in Clinical Immunology from Tarbiat Modares University, Tehran.  With over 20 years of experience in vaccine research and development, Dr. Banihashemi designed and developed Razi Cov-Pars, Iran's domestically produced COVID-19 vaccine. Under his leadership, Razi Institute successfully conducted Phase 1, 2 and 3 clinical trials of Razi Cov-Pars.this vaccine is first intranasal covid 19 vaccine in the world.

His research focuses on mucosal Immunity , intranasal vaccine , adjuvants, drug delivery systems, immune regulation and the development of bacterial and viral vaccines. He has published over 50 papers and authored book chapters in his field. His work on nanobody technology and immunoliposomes has applications for targeted drug delivery.

In addition to conducting research, Dr. Banihashemi teaches courses in infection and immunity. He has received several awards for his scientific contributions, including for exemplary research from Razi Institute. 

When not engaged in his own work, Dr. Banihashemi reviews papers for international journals. 

Lianpan Dai, PhD, Principal Investigator at Institute of Microbiology, Chinese Academy of Sciences. He received his doctor's degree from Technical University of Munich (TUM), Germany. His research is mainly focused on the design and development of novel vaccines against major pathogens and the mechanism of protective immune response. Important research and translational achievements have been made in the research and development of vaccines against coronaviruses, Zika virus and other emerging infectious diseases, among which the recombinant protein subunit COVID-19 vaccine has been approved for use in many countries. The results are published as first/corresponding authors in the journals including Cell, The New England Journal of Medicine, Lancet, Nature Immunology, Nature Reviews Immunology, Cell Host & Microbe. He is supported by the National Science Fund for Excellent Young Scholars, and is the winner of VCANBIO Award for Biosciences and Medicine, excellent member of the Innovation Promotion Association of Chinese Academy of Sciences, the Young Scholar Award of Chinese Society of Immunology, and China Patent Silver Award Winner.

Hani Kim is the Executive Director of the RIGHT (Research Investment for Global Health Technology) foundation, with 16 years of work experience in translational health research as an academic research scientist and at global health R&D funding organizations. She completed her PhD in Lab Medicine and Pathobiology at the University of Toronto, Canada and post-doctoral training in molecular immunology of B cells at the Max-Planck Institute of Immunology, Germany.

During her MPH and her affiliation as a Research Associate at the Johns Hopkins School of Public Health, Hani trained researchers at icddr,b, Bangladesh and KEMRI, Kenya. Prior to joining the RIGHT foundation, she developed and managed portfolios of vaccine discovery grants and molecular surveillance grants as a Gates Fellow initially and later as a Program Officer at the Bill & Melinda Gates Foundation for six years.

Hani has published articles in translational medical research and in the political origins of health inequity. Her recent articles include "The Selangor Consensus: strengthening clinical trials for local public health in the Western Pacific", ‘‘We need people’s WHO to solve vaccine inequity, and we need it now”, “The sociopolitical context of the COVID-19 response in South Korea”, and “A critical assessment of the ideological underpinnings of current practice in global health and their historical origins.”

Dr Norbert Pardi holds a Ph.D. in biochemistry and genetics. He has been working at the University of Pennsylvania since 2011 and currently holds an Assistant Professor position at the Department of Microbiology of the Perelman School of Medicine. His research interest is the development of mRNA-based therapeutics with particular focus on new generation infectious disease vaccines. He explored the development of a novel vaccine platform using nucleoside-modified mRNA in lipid nanoparticles (LNPs) and used it to generate highly effective vaccines targeting various pathogens (influenza virus, coronaviruses, malaria and others). Dr. Pardi is a pioneer of the nucleoside-modified mRNA vaccine technology and published milestone papers in the field.

Heinrich Haas， Department of Biopharmaceutics and Pharmaceutical Technology Johannes Gutenberg-Universität, Mainz Mainz, Germany. Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.

Mr. Jian Dong has 35 years’ experience in biopharma manufacturing, quality management and facility construction.

Joining WuXi Biologics in 2014, he is CEO of WuXi Vaccines and SVP of WuXi Biologics, previously SVP and Head of Global Manufacturing and Head of Global Engineering of WuXi Biologics responsible for the management and R&D of biological drug clinical and commercial manufacturing and construction of production facilities.

Mr. Dong has led team passing China’s first FDA PLI and EMA GMP inspection and obtaining approval of WuXi Biologics DS and DP manufacturing facilities as well as the design, construction, validation and delivery of various R&D centers and manufacturing sites of WuXi Biologics worldwide.

Before WuXi Biologics, he was Deputy Chief Engineer in Shenzhen Kangtai Biological Products, Senior Process Engineer in Eli Lilly & Co., U.S., VP of Manufacturing and VP of Quality in Shanghai Celgen Biopharma, Deputy General Manager in UBPL and Shanghai United Cell Biotechnology, Unilab’s subsidiary. During his tenure in China before joining WuXi Biologics, he made significant contribution to the approval of one NDA, four BLA and four GMP licenses, including the technical transfer of MSD’s recombinant hepatitis B vaccine to China.

As Senior Director at Sanofi Vaccines External R&D, Sean is responsible for the identification and evaluation vaccine-related opportunities to support Sanofi Vaccines’ global pipeline strategy. Under his leadership, Sanofi Vaccines has completed three research agreements, initiated over 10 feasibility studies with both academic and industrial partners, organized 4 full due diligence, executed two global licensing agreements with biotech companies, and reached a 280 million AUD collaboration agreement with Queensland State Government. Sean has over 20 years of extensive vaccine R&D and business development experience. Before joining Sanofi, Sean was Co-Founder and Chief Operating Officer at Altravax from 2013 to 2015 and Executive Director & Head of the Vaccine Research Institute at Simcere Pharmaceutical Group from 2010 to 2013. Prior to Simcere, he worked as a Senior Scientist and Project Leader on multiple vaccine programs at Maxygen for 9 years. Sean received his Ph.D. degree in Biological Sciences from the University of Delaware, M.S degree in Microbiology from the Institute of Microbiology, Chinese Academy of Sciences, and B.S. degree in Microbiology from Shandong University. He received his postdoctoral training at Columbia University.

Ms Adel Sattarova holds Specialist Degree in Pharmacy. She has been working at the Saint Petersburg Scientific Research Institute of Vaccines and Serums (FSUE SPbSRIVS FMBA of Russia) since 2016 and currently holds a Head of Project Management Department position. Ms Adel Sattarova has an experience in regulatory affairs, leads the projects, one of which is the WHO prequalification of the influenza vaccine FLU-M® – the product developed and produced by FSUE SPbSRIVS FMBA of Russia with a production site in Saint Petersburg, Russia and Managua, Nicaragua.

Ph.D. in Cellular and Molecular Biology by Oswaldo Cruz Foundation and the AIDS Vaccine Research Lab (UW-Madison-USA). Currently, she manages the RNA Vaccine Development Partner Center for PAHO/WHO at Bio-Manguinhos-FIOCRUZ, focusing on the development and manufacturing of RNA-based vaccines and therapies in Brazil. This initiative aims for regional self-sufficiency in vaccine R&D and production, democratizing the RNA platform for Latin America and the Caribbean. Awarded by Women in Science of PDA Brazil (2021) and SIBEN-Argentina (2022), she has 18 years of experience in Immunology, Vaccine and Biotherapeuticals Development, Public Health, and Equity.

Adham began his professional journey as a neuroscientist, followed by a shift to a commercial career at GSK Vaccines. He possesses over 15 years’ experience in commercialising biological therapeutics in the emerging markets namely Middle East and Africa, South East Asia and South America. He was responsible for obtaining emergency use approval for a prominent Chinese Biotech in the United Arab Emirates prior to China’s Approval. Having led biotech and clinical firms to achieve more than $250 million in revenue over the past 5 years. In addition to having established numerous start- ups, overseeing concept, value proposition, market analysis, business modeling, product development and securing investments. A seasoned health technology expert boasting years of experience in Machine learning and AI in the healthcare space.

王寒，北京大学未来技术学院副研究员，疫苗研究团队负责人。主要从事病毒感染机制和抗病毒干预策略研究，在包括埃博拉病毒、猴痘病毒和非洲猪瘟病毒在内的多种重要病毒性传染病原的入侵和复制机制、疫苗、抗病毒药物研究中取得了一系列重要进展。以第一和通讯作者（含共同）在Cell、Nature Immunology、PNAS、Nucleic Acids Research等国际期刊上发表论文多篇，获“2016年度中国生命科学领域十大进展”。入选博士后创新人才支持计划、北京市科协“青年人才托举工程”、中国科学院青年创新促进会；任 hLife 期刊青年编委，北京慢性病防治与健康教育研究会感染性疾病专业委员会委员。

Doctor Hu is the founder, chairman and full-time CEO of Anda Biology. She was a former researcher of the Chinese Academy of Sciences Shanghai Institute of Nutrition and Health, visiting scholar of the Max-Planck-Institute for Molecular Genetics in Germany, and visiting scholar of the Cambridge Molecular Biology Laboratory in the UK. She independently undertook key projects of the National Natural Science Foundation of China and 863 projects as the project leader, participated in the Super 973 projects, the Chinese Academy of Sciences' Leading Special Research on Stem Cell and Regenerative Medicine, and the National Twelfth Five Year Plan Major Special Projects. Expert in the Second Review of Outstanding Youth Fund, Outstanding Youth Fund, and Key Projects of the National Natural Science Foundation of China, and expert in risk assessment of the Ministry of Science and Technology in 2013.

She has been engaged in molecular genetics research of diseases for a long time and has established a series of genetic analysis techniques that can be applied to stem cell clinical transformation research such as stem cell quality control, in vivo genetic tracing, stem cell maintenance, and cell phenotype transformation, laying the foundation for stem cell based disease diagnosis and treatment. Dr Hu has published more than 70 SCI papers and won the first prize for scientific and technological progress in Shanghai (second place completion).

She has participated as the leader of the innovation team in 2018 in the first Shenzhen Women's Innovation and Entrepreneurship Competition. After winning the award, she founded Anda Biology Medicine Development (Shenzhen) Co., Ltd and she is serving as its full-time CEO. In the past four years, she has led the company's employees to develop personalized immunotherapy vaccine for pancreatic cancer, universal cancer vaccines, cell therapy and other products. Among which, PCNAT-1, a therapeutic personalized vaccine for pancreatic cancer, has won the FDA orphan drug qualification certification.

Graduated with a Ph.D. in Bioinformatics from the University of Science and Technology of China in 2014, under the guidance of Professor Liu Haiyan. Many years of experiences in molecular dynamics simulation and high-throughput sequencing, and have served as the Director of Bioinformatics for Micro Spin Genes and the Head of Nucleic Acid Drug Development for Yidu Cloud. Successfully developed multiple clinical high-throughput data analysis platforms and have authored multiple invention patent authorizations and SCI papers. As the co-founder of Therarna, responsible for identifying and optimizing upstream targets of mRNA drugs, leading the team to develop a systematic platform for identifying cross species cellular immune epitopes, designing humoral immune antigens, and optimizing mRNA sequences.

Dr. Hong Jin is the Chief Scientific Officer at CyanVac LLC. She has led the efforts to progress PIV5-vectored Covid-19 and Respiratory Syncytial virus (RSV) vaccines from preclinical studies to phase 1 and 2 clinical trials.  Prior to joining CyanVac, Dr. Jin was Sr. Director/Fellow at MedImmune and AstraZeneca responsible for viral vaccine development. She pioneered reverse genetic systems for influenza virus, RSV and Newcastle disease virus (NDV) and played critical roles in advancing candidate vaccines towards clinical trials and commercialization. She was instrumental in developing the strain selection process for annual commercial intranasal live attenuated influenza vaccine (FluMist) and clinical evaluation of pandemic influenza vaccines.  She has authored more than 100 publications during her scientific career. Dr. Jin was nominated as a 2023 PharmaVoice100 to recognize her contributions to infectious disease vaccine development.

Xiangrong Song is a full professor at Sichuan University and a pharmaceutical scientist at National Key Laboratory of Biotherapy. The Song lab has developed the targeted delivery systems for gene drugs and small molecules to treat tumors, atherosclerosis, ocular diseases, infection or brain diseases. Two novel drug candidates (IND) have been approved for phase I clinical trials. She has authored more than 100 papers and is an inventor of more than 50 issued / pending patents worldwide. The technologies that Dr. Song and her colleagues have developed formed the basis for the launch of 2 biotechnology companies. The two companies are translating the aforementioned academic innovations toward commercialization and societal impact. In 2019, she was a recipient of the first prize of Science and Technology Award in Chinese National Medicine Association, for the research on immune function of Yi nationality's medicine. In 2022, she was named as the elite of science and technology in China.

Dexiang Chen, Doctor of Immunology, Mississippi State University, has been engaged in the development of vaccines and vaccine adjuvants in Pfizer, Novartis and PATH scientific and technological organizations for more than 30 years, and has presided over a number of major international public health special projects funded by international organizations, foundations and national governments. Among the more than 20 infectious disease vaccine development projects presided over and participated in, many products have been listed globally. Dr. Chen Dexiang has published more than 60 vaccine-related academic papers in world-class academic journals such as Science and Nature Medicine.

Suthira Taychakhoonavudh (BSc, MSc, PhD) is a CEO and Co-founder of Baiya Phytopharm, a biotech spin-off company from faculty of pharmaceutical sciences, Chulalongkorn university, Thailand. Suthira is also an associate professor at the social and administrative pharmacy department at Faculty of Pharmaceutical Science, Chulalongkorn University with her research focus on health economics, health policy, access to medicine and health technology assessment. Her almost decade-long experience on pharmaceutical pricing and patient access has motivated her to co-founded Baiya Phytopharm with an aim to increase access to affordable medicines for patients in Thailand as well as the SEA region.

Li Jie is a doctor from China Agricultural University and a postdoctoral fellow at Cornell University. He serves as the R&D Director of Jinyu Group and is the Director of the Key Laboratory of Ruminant Biological Products under the Ministry of Agriculture. Additionally, he holds the position of Director of the Key Laboratory of Animal Infectious Disease Vaccine and Diagnostic Reagent Engineering Technology in the Inner Mongolia Autonomous Region. Dr. Li specializes in the development of advanced vaccine technologies, including mRNA vaccines, exosome-based vaccines, and AI-driven bioinformatics platforms. He has successfully led the establishment of China's first GMP-compliant production facility for animal mRNA vaccines, which received official approval in February 2024. Under his leadership, the African Swine Fever subunit vaccine and the feline infectious peritonitis mRNA vaccine—both groundbreaking products globally—were submitted for clinical approval in 2024. Dr. Li has integrated cutting-edge technologies such as AI, metagenomics, and bioinformatics to develop a digital vaccine system that enables high-dimensional omics analysis of animal populations across diverse regions. His research focuses on understanding the clinical manifestations of hosts under multi-pathogen conditions post-vaccination and identifying the root causes of vaccine efficacy. Dr. Li has led three key projects at the provincial and municipal levels and has contributed as a sub-project leader to two national key R&D programs. He was awarded first prize in the Eighth China Innovation Challenge Livestock and Swine Technology Competition. With 24 patent applications and over ten peer-reviewed publications.

Dr. Yelin Xiong is the Vice President at Yither Biotech Co. Ltd. In this role, she is responsible for early-stage discovery to clinical material manufacturing of various vaccine candidates. Yelin has extensive research experience in immunology and vaccine development against infectious diseases. Prior to the current position, Yelin had over 20 years of industry experience in research, process development/scale-up, GMP manufacturing and CMC management in Sanofi pasteur. She received a Doctorate degree in Immunology and Cell Biology from John Curtin School of Medical Research, Australian National University and had postdoctoral training in Emory University and University of Toronto.          

Dr. Frank Chia-Jung Chang obtains his Ph.D. from Life Science and Institute of Genome Science department of Taiwan Yang-Ming Medical University in 2012. He received his postdoctoral training at Molecular Biology Institute of Academia Sinica (Taiwan) and worked as visiting scholar in Frances H. Arnold’s laboratory (Nobel Prize in Chemistry winner in 2018), Chemical Engineering Department of Caltech (U.S.). He joined Reber Genetics as the supervisor of R&D Division in 2014. From 2017, Frank also works for business development and strategic layout of vaccine products (technology included).

Dr. Chang has considerable expertise in virology, microbiology, reverse vaccinology and protein engineering for industrial production. His group has successfully developed novel subunit vaccines of swine PRRSV, pan-PCV, Mycoplasma, CSFV and PEDV in Reber Genetics, furthermore, also support the study of safe vector vaccine against ASF with external partners.

Dr. Berlanda Scorza is an accomplished pharmaceutical executive with a strong focus on translating scientific innovations into tangible patient benefits. He currently serves as Vice President of Global Health R&D Vaccines at GSK. Additionally, he is the Chairman of the Board and General Manager of the GSK Vaccines Institute for Global Health, as well as a member of the GSK Country Executive Board in Italy.

Before joining GSK in 2020, Dr. Berlanda Scorza held senior leadership roles at the Bill & Melinda Gates Foundation and PATH, where he led key programs focused on the development of seasonal and pandemic influenza vaccines.

Earlier in his career, Dr. Berlanda Scorza was a senior scientist at Chiron Corporation and Novartis Vaccines, where he contributed to the development of innovative vaccine technologies, including a replicon RNA vaccine, the cell-cultured influenza vaccine Flucelvax, and the bacterial vaccine platform GMMA. Dr. Berlanda Scorza earned his Ph.D. from the University of Milano-Bicocca and completed his post-doctoral research at Imperial College London.

英博博士于2019年创立艾博生物，为公司创始人、董事长兼首席执行官。创立至今，艾博生物已建立起具有自主知识产权的mRNA和纳米递送技术平台，推动mRNA科学技术应用赋能创新医疗产品开发。

英博博士拥有国际化的行业视野和丰富的核酸药物开发领域工业界经验，精通RNA药物设计和纳米制剂产业化。创立艾博生物前，他曾在多家全球领先的核酸药物研发机构任核心研发团队负责人，领导开展包括小核酸（siRNA）、mRNA及基因编辑产品的开发及大规模工业化生产等工作。

英博博士本科、硕士毕业于复旦大学，并在美国东北大学获得药剂学博士学位。英博博士曾在Cell、Lancet等多个重要国际期刊发表论文，他也是多项海外授权专利发明人。2018-2019年期间，英博博士任波士顿美中生物医药协会（Chinese-American BioMedical Association）会长，服务生物医药科研和工业技术的深度融合。

Peter Dull is the deputy director for Integrated Clinical Vaccine Development within the Global Health Division. In this role, he provides technical and strategic guidance on clinical development to the foundation’s program strategy teams, including Pneumonia and Enteric and Diarrheal Diseases, and external partners. In addition, he leads the foundation’s vaccine development activities for HPV vaccines, including efforts with reduced dose schedules.

Peter joined the foundation in 2014 after 10 years at Novartis Vaccines and Diagnostics where he was the clinical franchise head for Meningitis and Sepsis Vaccines. During that time, he led the clinical development and global licensure for a quadrivalent meningococcal glycoconjugate vaccine (Menveo; MenACWY-CRM) as well as a protein-based serogroup B meningococcal vaccine (Bexsero; 4CMenB). His work also included early clinical development of Group B strep glycoconjugate and Staph aureus vaccines. Prior to joining Novartis, he was an epidemic intelligence service officer in the Meningitis and Special Pathogens Branch at the U.S. Centers for Disease Control and completed subspecialty training in infectious diseases at Emory University.

He received his medical degree at University of Wisconsin-Madison and Internal Medicine training at Oregon Health Sciences University.

李浩，中国农业大学动物医学院副教授，博士生导师。2017年7月在清华大学获得理学博士学位。2017年7月到2019年7月在清华大学医学院从事博士后研究工作。2019年7月至今，在中国农业大学动物医学院从事结核病免疫学和抗生素耐药性相关研究。主持国自然面上和中国博士后基金各1项，国家重点研发计划研究任务1项，参与国自然3项。以第一或通讯作者（含共同）在Nature Reviews Immunology，PNAS，Nature Communications，npj Vaccines等杂志发表相关文章30余篇。

Dr. Jiangsheng Xu is the Founder and Chief Scientific Officer of General Therapeutics, Inc., specializing in the development of non-reactogenic lipid nanoparticle (LNP) technologies aimed at overcoming challenges in mRNA vaccine hesitancy and RNA medicine re-dosing. With over 15 years of hands-on experience in nanoparticle and RNA research across both academic and industry settings, Dr. Xu has contributed to leading journals, including Nature Nanotechnologyand Nature Communications, and holds 10 patents.

Dr. Emanuele Andreano is an immunologist with almost 10 years of experience studying B cell and antibody responses to human pathogens, and he is currently project leader at the Monoclonal Antibody Discovery Laboratory (MAD Lab), Fondazione Toscana Life Sciences, directed by his mentor Prof. Rino Rappuoli. During his training, Dr. Andreano gained extensive experience on single cell sorting of memory B cells and isolation, cloning, expression and functional/structural characterization of human monoclonal antibodies. This experience has been used to tackle different pathogens which pose serious threats for global health such as the respiratory syncytial virus (RSV), antimicrobial resistant Neisseria gonorrhoeae, SARS-CoV-2 and more recently the Monkeypox virus. The work that Dr. Andreano performed on SARS-CoV-2 led to the isolation of more than 14,000 thousand human monoclonal antibodies and to the identification of MAD0004J08, one of the most potent monoclonal ever described and evaluated in a phase II/III clinical trial for the treatment of COVID-19. Dr. Andreano first authored publications on top tier journals such as PNAS, Cell, Nature Medicine and Nature. For his scientific work, Dr. Andreano has been awarded the “COVID-19 heroes award” and has been nominated as “Rising Star” in the field of immunology by the International Union of Immunological Societies (IUIS) 2023.

Professor Han Xuexiang is a researcher, project leader and doctoral supervisor of the Center of Excellence in Molecular and Cell Science, Chinese Academy of Sciences.

Selected in the national high-level talents (overseas) project and Shanghai Leading Talents (overseas) project.

Hanz Biotechnology (Suzhou) Co., LTD., Co-founder & CSO.

He received his bachelor's degree from Shanghai University in 2014, and his PhD from Tsinghua University in 2019 (jointly trained by National Center for Nanoscience and Technology). From 2020 to 2024, he worked as a postdoctoral researcher in the laboratory of Professor Michael J. Mitchell, University of Pennsylvania, USA, during which he collaborated with Professor Drew Weissman, winner of the Nobel Prize, on the research of LNP-mRNA vaccines and drugs. In February 2024, he joined the Center of Excellence in Molecular and Cell Science, Chinese Academy of Sciences. His research focuses on the construction of novel LNP and RNA drug delivery. He is the first-author (including co-first author) of Nat.Chem., Nat.Nanotech., Nat.Mater., Nat.Commun. He has published nearly 20 papers in other journals, authorized one Chinese patent, and applied for a number of PCT patents.

Prof Keith Chappell

Australian Institute for Bioengineering and Nanotechnology, and School of Chemistry and Molecular Biosciences, The University of Queensland, Australia

Prof Keith Chappell is a Molecular Virologist whose research is focused on structure-based design of vaccines for medically important viruses. Keith is one of the inventors of the broadly applicable vaccine platform, molecular clamp. Molecular clamp locks viral glycoproteins into the native prefusion conformation to elicit highly protective immunity and enables consistent manufacture of highly stable, ready-to-use, fully liquid vaccines. Keith leads a team of 20 staff and students split across two major research programs: The CEPI funded Rapid Response Vaccine Pipeline which seeks to safeguard against future pandemics and contract research conducted for the UQ biotech spinout company Vicebio Ltd. In 2020, Keith co-led the University of Queensland’s effort to produce a covid vaccine, which progressed from sequence information to clinical trial dosing within 6 months, however did not progress due to interference with some existing HIV diagnostic tests. Since that time this team as produced a new covid vaccine incorporating a second-generation molecular clamp that has completed clinical testing showing favourable safety and immunogenicity profile in comparison to approved covid vaccine, Nuvaxovid (Novavax). Vicebio is also actively advancing this technology for the development of multivalent vaccine formulations to target life-threatening respiratory viruses, with a bivalent vaccine for Respiratory Syncytial virus and human metapneumovirus is currently undergoing phase I clinical trial testing.

Dr. Chen has been a Professor at the State Key Lab of Respiratory Disease, Guangzhou Medical University since 2013. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He obtained a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.  From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor of Merck's Ad5-based AIDS vaccine that entered clinical trials worldwide. Dr. Chen served as Vice President of R&D for GlaxoSmithKline in 2009-2011 and as Vice President at Sanofi Pasteur in 2012. Dr. Chen has over 200 publications in infectious diseases, vaccine research, and cancer research. His current research is focused on vaccine and antibody research on adenovirus, influenza virus, and emerging viruses. Since 2020, Dr. Chen has been working on developing user-friendly intranasal vaccines and mucosal immunity.

Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, the early development of DNA encoded genetic adjuvants including the particularly relevant IL-12, advances in gene optimization, and advances in electroporation (EP) technologies resulting in improved gene delivery among others. His group worked with collaborators to become the first to move DNA technology into human study. His laboratory’s work helped revitalize the field through advancement of new synthetic DNA design and modification of EP delivery approaches resulting in potent immune induction as well as the first successful Phase IIb DNA efficacy study (for HPV immunotherapy) in humans. Dr. Weiner is the recipient of numerous honors including election as a fellow to both the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He is the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immunotherapy. In 2019, Dr. Weiner was honored with the Scientific Achievement Award from Life Sciences PA (LSPA). Dr. Weiner returned to Wistar in 2016 from his position at The University of Pennsylvania School of Medicine as professor of Pathology and Laboratory Medicine. From 1990 to 1993, Weiner held a joint position as assistant professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine. Dr. Weiner is a co-founder of Inovio Pharmaceuticals and is a member of the Board of Directors. Dr. Weiner graduated with a B.S. in biology from SUNY at Stony Brook, N.Y., a M.S. in biology from the University of Cincinnati and a Ph.D. in developmental biology from the University of Cincinnati College of Medicine.

After obtaining his PhD in Biological Chemistry from the Johns Hopkins University, Dr. Wang started his industry career and worked at a number of biotech and pharmaceutical companies, including Grifols S.A., Novartis, and GSK Vaccines, during which he rose from scientist to leadership roles and accumulated rich vaccine and drug development experience, especially with self-replicating RNA. After leaving GSK, Dr. Wang co-founded Immorna Biotherapeutics. Under his leadership, Immorna has built cutting-edge and proprietary mRNA platform technologies and developed rich clinical pipeline spanning infectious diseases, immune-oncology, and rare genetic disease areas.

Michel De Wilde holds a PhD in Biochemistry and has a long and successful career in Vaccine Research and Development. He currently consults for the vaccine community and is member of several Scientific Advisory Boards

From  2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at sanofi pasteur where he drove the development and licensure  of a number of products.

From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility. He played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine.

George Simeon is the CEO of Curevo Vaccine. He joined Curevo at the beginning of 2019 and has over 30 years of experience in the healthcare sector working with multinational firms, start-ups, and not-for-profits. He has worked in biotech, pharmaceuticals, medical devices, IVD, and healthcare convergence technologies. He has worked extensively in Europe, Asia, and North America.

Before moving to the USA, he was based in South Korea from 2014-2018, where he worked for SK Telecom’s Healthcare Division in M&A and global strategic alliances. In 2016, he joined Sollers Partners, a cross-border investment advisory firm, while maintaining an advisory role with SK Telecom.

He has worked across Europe and the USA as an executive with Johnson & Johnson, as the founding Vice-President of Cordis Neurovascular Europe, and with GHX Europe as a Commercial Vice-President. He also spent 3 years with Novartis Global Headquarters in Switzerland working on projects in their CNS portfolio in Health Economics and Pricing.

George has also founded two start-ups and advised GS1 on their global entry and expansion into the Healthcare, High-Tech, and Customs sectors as well as on ESG practices in FMCG logistics.

George is a graduate of INSEAD (MBA) and Yale University (MPH).

Dr. Alejandra Capozzo has an MD in Biology from the University of Buenos Aires (UBA), Argentina. She is a Doctor in Biotechnolgy also from the UBA. Her PhD thesis focused on alternative vaccines against foot-and-mouth disease directed by Dr José La Torre. She did postdoctoral studies in neonatal applied immunology at the Center for Vaccine Development (CVD) at University of Maryland (Baltimore, USA), where she worked on the development of new vaccines for neonates in the presence of maternal immunity. She has intensified her training in immunology at the National Academy of Medicine in Buenos Aires, focused on vaccines against Uremic hemolytic syndrome and animal models. Dr Capozzo worked as Market Development Manager for Latin America at Prionics (a Swiss company); and as leader of research and development in Biogenesis-Bagó, an international veterinary vaccine producer. She is also trained in sales management.

From 2008 to 2023 she was the head of the applied veterinary immunology laboratory at the Institute of Virology and Technological Innovations, a CONICET-INTA. She is currently Principal Researcher of the Argentinean national research council (CONICET), the CEO of the Global Foot and Mouth Disease Research Alliance (GFRA), President of the Argentine Association of Veterinary Immunology, coordinator of the Latin American Veterinary Immunology Network, and the Chair of the Veterinary Immunology Committee of the International Union of Immunological societies (VIC-IUIS). Dr Capozzo participates in several transboundary disease groups in FAO-WOAH, as the co-chair of the Global Coordination Committee on Foot and Mouth Disease (GCC-FMD) and as a member of the Partnership and Financial panel (PFP).

Dr Capozzo has been a professor of immunology at the School of Veterinary Medicine of the University of Buenos Aires for many years and directed 14 PhD theses. She is the Responsible Researcher of numerous national and international projects and has developed several products related to applied immunology that were transferred to Argentine and international companies. She is currently the Director of a Center focused on One health, located at the Interamerican University in Buenos Aires, since February 2024.

Arnaud Didierlaurent is an engineer in Biotechnology by training and an immunologist with a PhD in cellular immunology from the University of Lausanne in 2003 (Jean-Pierre Kraehenbuhl). Arnaud continued his work on innate immunity in the lab of Jürg Tschopp before joining the Imperial College, London, where he worked as postdoctoral fellow from 2004 to 2007 on the long-term impact of viral infection on the lungs. He was also a research fellow in Ralph Steinman's lab at the Rockefeller University in New York. Arnaud then joined the R&D department of GlaxoSmithKline in 2008 in Belgium, where he held several leading positions in vaccine research and development. Initially head of a lab investigating the mode of action of adjuvant, Arnaud became in charge of the GSK Adjuvant System portfolio and thus directly involved in the licensure of several adjuvanted vaccines.

Arnaud’s scientific contributions have consequently been focused on deciphering the interplay between innate immunity and pathogen/vaccine-specific adaptive response. With his experience in both academic and industrial settings, Arnaud has acquired a deep understanding of how vaccines are created, developed and deployed. He joined the University of Geneva in March 2020 to continue his work on translational vaccine research. He is acting as the chairman of the WHO Technical Advisory Group who provides recommendations for the Emergency Use listing of COVID-19 vaccine candidates. Since February 2023, he is an associate professor and the director of the Center of Vaccinology at the Faculty of medicine. 

Rita Carsetti trained in Medicine and Obstetrics and Gynecology at La Sapienza University of Rome (Italy) before discovering her passion for science during her postdoctoral training in the United States, at the M.D. Anderson Hospital in Houston (Texas). She followed this with a second postdoc at the Max-Plank Institute for Immunobiology in Freiburg (Germany), in the department of Georges Koehler, who had received the Nobel Prize for the discovery of monoclonal antibodies. At the Max-Planck she also became responsible for the flow cytometry core facility and later worked in the departments of Michael Reth and Thomas Boehm. After 13 years in Germany, she returned to Italy (Bambino Gesù Children’s Hospital, Rome) with a strong background in basic immunology of murine B cells. At this point she turned her attention to human B cells for a more patient-orientated research approach. The close contact with clinicians and her role as head of the Diagnostic Immunology Unit gave her the possibility to learn how human B cells change with age, immunodeficiency, infection, transplantation, and vaccination. The COVID-19 pandemic and the global vaccination campaign gave her the possibility to learn more about the development, function, and persistence of human memory B cells after vaccination in healthy subjects and patients with primary or secondary immunodeficiencies. Throughout her career, Rita Carsetti has made a number of discoveries regarding the development of human and murine B cell populations and the effect changes in such populations have on infection and immunodeficiencies in humans. Her recent work on SARS-CoV-2 and RNA vaccination has been vital in demonstrating how human memory B cells aid immune protection and how mucosal immunity is induced in neonates born to SARS-CoV-2 infected mothers. Altogether, Rita Carsetti’s work is extremely relevant to both basic and clinical immunologists.

Dr. Chen is a prominent scientist specializing in human vaccine research and antiviral therapies. He currently serves as the Chief Operating Officer at RuenHuei Biopharmaceuticals Inc., where he oversees the development and production of new vaccine candidates. Dr. Chen joined RH Biopharma in August 2018, bringing over a decade of practical industry experience in vaccine development. Before his role at RH Biopharma, Dr. Chen held several key positions at Adimmune Corporation, including the Director and Manager of the R&D Department. At Adimmune, he was instrumental in developing the EV71 vaccine and advancing a cell culture-based production process for influenza vaccines. Dr. Chen's academic background includes a Ph.D. from National Yang-Ming University in Taipei, Taiwan, where he specialized in Biochemistry and Molecular Biology. He also completed postdoctoral fellowships at the Genomics Research Center, Academia Sinica, and the Vollum Institute at Oregon Health and Science University in the United States. His research has significantly contributed to the field of vaccine development, particularly in creating more effective influenza vaccines and understanding the immune responses to viral infections. He is currently also special technical expert at the Department of Pharmacy at National Taiwan University and an associate professor at the Department of Chemistry at National Chung Hsing University

Dr. Hui  Li is a dedicated professional who is currently serving as the Director of  R&D at Innorna. Her work specializes in the research and development of  vaccines for infectious diseases. With her vast experience in the life  sciences industry, she has been involved in numerous vaccine development  projects and has conducted extensive research in this field. As a leader of  the vaccine R&D team at Innorna, Hui continuously innovates and has  successfully developed several mRNA infectious disease vaccines, which are currently undergoing clinical trials.  Founded in 2019, Innorna is a platform-based delivery technology company primarily focused on developing nucleic acid drug delivery technologies. It is among the few global high-tech firms that have mastered the LNP technology, with a proprietary mRNA platform technology. Leveraging the LNP and mRNA platform technologies, Innorna has developed pipelines for infectious disease vaccines, rare diseases, and tumor immunotherapies.

Yasuo Yoshioka， PhD

Group Leader，The Research Foundation for Microbial Diseases of Osaka University

Education;              

1995-1999; Faculty of Pharmaceutical Sciences, Osaka University (Awarded the degree of B.S.).

1999-2001; Graduate School of Pharmaceutical Sciences, Osaka University (Awarded the degree of M.S.).

2001-2004; Graduate School of Pharmaceutical Sciences, Osaka University (2004; Awarded the degree of Ph.D. from Osaka University)

Brief chronology of employment;

2004-2006; Research Scientist, National Institute of Health Sciences (Tokyo, Japan)

2006-2012; Specially Appointed Associate Professor, The Center for Advanced Medical Engineering and Informatics, Osaka University (Osaka, Japan)

2012-2014; Associate Professor, Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University (Osaka, Japan)

2015-2020; Specially Appointed Associate Professor, Vaccine Creation Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University (Osaka, Japan)

2020-2024; Specially Appointed Professor, Vaccine Creation Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University (Osaka, Japan)

2015-Present: Group leader, The Research Foundation for Microbial Diseases of Osaka University (Osaka, Japan)

Yoshimasa Takahashi, PhD, graduated from University of Tokyo. He received his postdoctoral training at the University of Maryland at Baltimore, where he worked on understanding the basic mechanisms for humoral immune memory and antibody responses. He joined the National Institute of Infectious Diseases (NIID) in Japan, and became Director at the Department of Immunology. He was appointed to Director of the Research Center for Drug and Vaccine Development, NIID in 2021. He also holds the position of Guest Professor at seven universities. In this role, he trains graduate students in Immunology and Vaccinology.

Dr. Takahashi's research focuses on comprehending lymphocyte biology to unravel the humoral and cellular immune responses that underly vaccine effectiveness. By implementing high-throughput approach for human antibody analysis and isolation, he has identified novel classes of broadly protective antibodies against influenza, SARS-CoV-2, and other viruses. Multiple R & D for next-generation of vaccines and antibody therapeutics are on-going based on these findings.

Pei-Yin is leading the Preclinical R&D at Hilleman Laboratories. She has more than 20 years of experience in virology and close to 10 years of experience in vaccine development. She obtained her PhD from University of Wisconsin-Madison, and pursued her postdoctoral training at Wadsworth Center, New York State Department of Health and the University of Wisconsin-Madison. Her industry experience started when she joined Sentinext Therapeutics in Malaysia, developing vaccines against enteroviruses. After Sentinext, she joined Singapore Immunology Network (SIgN), A*STAR, Singapore to develop therapeutic antibodies against viruses. She joined Hilleman Laboratories in 2021 as a Senior Scientist, and is currently the Senior Manager at Hilleman leading the Preclinical team.

Mr. Lake has worked in vaccine manufacturing and commercialization for 30 years developing diverse experience at global leaders Merck and GlaxoSmithKline. Mr. Lake's background includes live virus and recombinant vaccine bulk production, sterile filling, and quality control, before moving into product management and business development roles. He served as the manufacturing Alliance Manager between Merck and Sanofi Pasteur during the startup of their European loint Venture and worked for several years as asenior level commercialization consultant in the vaccine industry.

司龙龙博士，中国科学院深圳先进技术研究院合成生物学研究所研究员、博士生导师，定量合成生物学全国重点实验室副主任，国家高层次人才（青年），国家重点研发计划首席科学家。博士毕业于北京大学，在哈佛大学Wyss研究所、哈佛医学院完成博士后研究工作。实验室研究方向包括合成生物学驱动的疫苗技术、人类器官芯片、抗病毒药物。发表论文约50篇，其中代表性研究成果以通讯作者、第一作者（含共同一作）发表于Science、 Nature Biotechnology、Nature Microbiology、Nature Biomedical Engineering、Nature Chemical Biology、Science Advances、Nature Communications等专业期刊，申请和授权专利20余项。

顾江，陆军军医大学国家免疫生物制品工程技术研究中心副主任、教授，博士生导师，国家重点研发计划首席科学家，“国防优才基金”获得者，军队高层次青年英才，陆军科技英才，陆军军医大学科研名师，享受军队优秀专业技术人才津贴。国家重点领域严重感染致病菌疫苗研发创新团队核心骨干；重庆英才创新创业示范团队核心骨干。中国疫苗行业协会细菌感染与疫苗研究专委会常委、秘书长，重庆微生物学会理事。先后获重庆市技术发明一等奖、军队科技进步二等奖等奖励。主要从事结构疫苗学基础与临床研究，围绕超级耐药菌的免疫干预展开，研制了1.1类新药——基因工程铜绿假单胞菌疫苗实现成果转化，合同金额2.8亿元。

张骞，深圳康泰生物国际事业部总经理，中国疫苗行业协会疫苗国际合作促进分会委员，毕业于同济大学经管学院和法国ESSEC商学院，负责公司国际商务拓展、国际注册和国际合作工作。曾成功引进包括人二倍体细胞狂犬疫苗生产技术、灭活脊灰疫苗生产技术等多个核心疫苗生产技术。同时与多个新兴市场国家开展了产品海外商务拓展、注册和申报工作，已向东南亚、南亚、中东等国家出口部分产品的成品和中间产品，并正在推进在东南亚、南亚、中东、拉丁美洲、独联体、非洲等国家的成品注册、原液分装和技术转移工作。同时与驻华使领馆、跨国药企、国际研究所、国际组织等展开了丰富的交流与合作。

Dr. Yuhong Cao is a scientist and principal investigator at the National Center of Nanoscience and Technology, Beijing, China. She earned her B.S. in Chemistry from Linfield College in Oregon, USA, and her Ph.D. in Materials Science and Engineering from Stanford University, California. Under the mentorship of Professor Nicholas Melosh, her doctoral research focused on developing a nondestructive nanostraw system for longitudinal living cell sampling. Following her Ph.D., Dr. Cao pursued postdoctoral training in T cell engineering by applying CRISPR-Cas technology. She worked with Professor Peidong Yang, in partnership with Professor Jennifer Doudna at the University of California, Berkeley. She then returned to Stanford University for a second postdoctoral fellowship with Professor Steven Chu, focusing on in vivo single-molecule tracking. At the National Center of Nanoscience and Technology, Dr. Cao leads a research group specializing in Nanomaterials and Plant Cell Surface Interfaces. Her work aims to develop universal intracellular delivery systems for natural plants to accelerate plant breeding. By exploring nanomaterials to facilitate effective gene editing using CRISPR technology, her lab addresses the critical need for efficient delivery systems in plants. This research has the potential to significantly shorten plant breeding cycles, enabling ultra-fast breeding and advancing agricultural innovation.

梁重阳教授专注于重组蛋白大分子药物开发领域，多年从事药物作用机制相关结构生物学研究及理化分析工作，主导研发多项创新型单抗药物和亚单位疫苗，通过成果转化与企业合作推动管线在美国FDA和中国NMPA获批临床试验或上市。

Dr. Xinzhong (Jon) Wang, Ph.D. currently serves as the Global R&D President and CSO of Parr Biotechnology (He Bei) Co. Ltd.

He was the Founder and CEO of Fusion Bioscience (Cayman) Inc. incorporated in November 2021.  Fusion Bioscience merged with Parr Bio in 2023. Dr. Wang is a scientific leader with over 20 years of experience in oncology research and drug development. He has extensive knowledge and experience in tumor immunology, molecular and cell biology, drug target discovery, animal modeling, and protein therapeutics development. He has published more than 30 original scientific papers in prestigious journals and is the inventor of several international patents.

Prior to Parr Bio, Dr. Wang served as Senior Vice President and Chief Scientific Officer at CStone Pharmaceuticals (HK02616); Director of Immuno-Oncology research at Merck & Co.; Associate Director of BioSuperiors at AstraZeneca/MedImmune;  Principal Scientist at Biogen.

Dr. Wang obtained a Bachelor of Science degree in Biochemistry from Nankai University and a PhD in Molecular and Cellular Biology from Ohio University. He completed his post-doctoral training in Gene Therapy at Harvard Medical School/Massachusetts General Hospital and subsequently served as an Instructor of Medicine at Harvard Medical School.

魏霞蔚，四川大学华西医院研究员，博导，长江学者特聘教授，国家优秀青年基金获得者。 2010年毕业于浙江大学药物制剂系毕业获得学士学位，于四川大学华西药学院药剂系毕业获得博士学位。现任四川大学华西医院国际合作与交流办公室·港澳台事务办公室主任。任国家老年疾病临床医学中心副主任，华西医院老年与衰老医学研究室主任。任美国基因与细胞治疗协会分委会委员，任亚太地区基因/细胞治疗联盟青年主席。主要研究方向包括：重组蛋白疫苗与佐剂研发、鼻喷疫苗与新型疫苗递送系统、肺部炎性疾病与肿瘤免疫微环境研究、抗肿瘤小分子药物的转化研究等。在 Nature、Nature Communications、EMBO Molecular Medicine、Advanced Science、Molecular Cancer、ACS Nano等发表SCI论文，其中以通讯作者或第一发表SCI论文110篇(H-index=56)。担任4种SCI杂志的编委（Editorial Board Member）或副主编，获得2018年药明康德学者奖。

Hua Peng, Ph.D., Principal Investigator at the Guangzhou National laboratory (GNL). Dr. Hua Peng graduated from Peking University, Health Science Center with a bachelor's degree, and completed his doctoral and postdoctoral training in virology at the State University of New York at Buffalo and the National Institutes of Health (LVD/NIAID/NIH). Prior to joining GNL, Dr. Peng held positions as associate Prof./Prof./PI at the Institute of Biophysics, Chinese Academy of Sciences. Her research focuses on 1) Investigating host immune response to virus infection, viral pathogenic mechanism, and virus-associated malignancy; and 2) Developing innovative preventive and therapeutic vaccines against viral infections and immune based anti-cancer drugs. Dr. Hua Peng has made important scientific and translational achievements, publishing in prestigious journals including Gut, Cell Res., Sci Immun., JEM, JCI, Gastro, Nat Commun., PNAS, Nat Med, Nat Immun., Hepatology, Clin Can Res, JI, JBC, and JV. Prof. Peng’s team invented a new-generation SARS-CoV-2 recombinant vaccine, leading to the approval of the vaccine product V-01 and its iterative vaccine BV-01-QX for emergency use in collaboration with Livzon Bio.

Ph.D. in Molecular Virology from Wageningen University, the Netherlands. Formerly served as a researcher at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) in Canada, the Australian National University, and the University of Amsterdam, focusing on the molecular pathogenesis of influenza virus, respiratory syncytial virus, and baculovirus, as well as vaccine development for respiratory diseases. Currently employed at CanSino Biologics Inc. as a Senior Scientist in the R&D Center. Leading and driving major R&D projects and international collaborations within the company. As a project leader, working on the development of an inhaled adenovirus-vectored tuberculosis vaccine and dedicated to advancing mucosal vaccines and novel vaccine delivery technologies.

Dr. Eric Tsao has served as the Chief Executive Officer of Synermore Biologics since the founding of the company in 2013.  He has over 25 years of direct experience with more than 20 products in clinical development, four US and EU approved products on the market, and eight biotech manufacturing facilities.  His areas of expertise include biological product development, process design, facility engineering, and operations.  Under his leadership, SYN023, an innovative anti-rabies monoclonal antibody cocktail, has been expertly developed and commercialized for rabies post-exposure prophylaxis.  Since 2008, Dr. Tsao has worked with Morningside Group on biotech investments.  He was instrumental in enhancing portfolio companies’ CMC capabilities. Dr. Tsao was the Vice President of Technical Operations at Aeras, a Gates Foundation sponsored vaccine development organization.  At MedImmune, Dr. Tsao rose to the position of Vice President of Process and Manufacturing Sciences responsible for process development as well as manufacturing of monoclonal antibodies and recombinant vaccines.  The development and manufacturing efforts led to the successful licensing of Synagis, FluMist, and Cervarix.  He was a process development scientist at Johnson & Johnson, where he focused on the development of cell culture processes and start-up of the commercial manufacturing facility for erythropoietin.  Dr. Tsao received his Ph.D. in Chemical Engineering from the University of Michigan.

Dr. Xu Gelin, senior  expert of  Wuhan Institute of Biological Products (WIBP), experienced on vaccine development for nearly 40 years. 

冯华朋，浙江理工大学-依思康医药创新佐剂和新型动物疫苗研发中心副教授，硕士生导师。博士师从我国著名禽流感专家陈化兰院士，日本东京大学医科学研究所博士后。主要研究方向为流感病毒与宿主相互作用及新型疫苗免疫佐剂研发。主持国家自然科学基金面上项目、浙江省自然科学基金等多项课题。发表SCI论文23篇，申报国际专利和国家发明专利9项，参与多株高致病性禽流感疫苗研制，日本病毒学会会员并担任Veterinary Vaccine 青年编委及多个SCI期刊的审稿专家，绍兴市“名士之乡”特支计划青年拔尖人才，参与编制佐剂团体标准4项。

刘存宝博士是中国医学科学院医学生物学研究所研究员，国家重点研发计划青年科学家项目负责人。近年来，以第一/通讯作者发表研究论文数十篇，授权国内发明专利5项。刘博士的实验室主要关注新佐剂亚单位疫苗和 mRNA 疫苗研究，尤其是此类疫苗诱导的细胞免疫 （CMI）。CMI 对潜伏感染病原体的疫苗至关重要，且可能对粘膜感染病原体的疫苗有贡献。他今天的主题是“一种产能不受限的经济型佐剂可在亚单位疫苗中诱导高效细胞免疫”。

Ms. WANG is responsible for the company's overall commercial operation in both China and Overseas markets. She has 23 years experience in pharmaceutical industry and holds a bachelor degree in Economics, a master degree in engineering of Peking University and Global EMBA of CEIBS. Jeanne joined the Company in 2012 and made outstanding achievements in multiple roles such as Head of HR, Head of Operation, Vice President of Strategy & Business Development and Chief Financial Officer. She helped the company set up the management system of financing, financial operations, human resources and commercialization. After completing several rounds of Pre-IPO fund raising, Ms. Wang also successfully led the Company’s IPO on Main Board of Hong Kong Stock Exchange in 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in 2020, making the Company the first “A+H” dual listing vaccine company.

袁瑗女士是帕斯适宜卫生科技组织（PATH）上海代表处中国国家代表。她负责管理PATH与中国伙伴的合作关系，并为PATH在中国提供管理和业务发展支持。她于2007年1月加入PATH，担任过包括项目管理、行政财务官员等多项职务，在疫苗领域从业18年间，参与了乙脑疫苗世卫组织预认证、轮状疫苗开发、肺炎结合疫苗开发和培训、OPV海外临床、Sabin IPV D抗原国际标准制定、HPV疫苗预认证等项目，熟悉疫苗生命周期的生产、质量、临床、药政、药物警戒、生物安全等多个方面。2023年1月，袁瑗女士被选举为中国疫苗行业协会疫苗国际合作促进分会第一任秘书长。在加入PATH之前，她在新加坡Integrity Metals公司担任项目经理并在印尼工作。袁女士在北京大学获得文学学士、工商管理硕士和公共卫生硕士学位。

Dr. Yan graduated and earned his B.S. and Ph.D at Wuhan University. He continued to work as a teaching staff member in College of Life Sciences, Wuhan University until 1998. From 1998 to 2002, he worked with Prof. Michael E. Lamm as a Research Associate in Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio and conducted scientific research on mucosal immune functions of IgA in relation to virus infections. He returned to Wuhan University in autumn 2002 and joined in the newly established Modern Virology Research Center, College of Life Sciences, Wuhan University as an associate professor. In 2006, he moved to the Wuhan Institute of Virology, Chinese Academy of Sciences, where he was appointed as a professor and group leader to set up an independent research lab named Mucosal Immunity Research Group. His lab is a group member of the State Key Laboratory of Virology in China. He has continued his research on the mucosal IgA functions against virus infections and focused more on the intra-epithelial activities of IgA against viral non-surface and non-structure components, which helps to reveal novel anti-viral mechanisms of IgA antibodies. His lab demonstrated that measles virus (MV) non-surface protein such as matrix protein (M), non-structural protein such as phosphoprotein (P) specific IgA can interact with viral newly synthesized proteins during IgA transport through the viral infected epithelial cells, and inhibit viral replication intracellularly. He also extended his study in developing optimized recombinant flagellin as mucosal adjuvant for designing novel subunit mucosal vaccines. He obtains 3 patents issued by the United States Patent and Trademark Office and 4 patents issued by the State Intellectual Property Office of the PRC related to novel flagellin adjuvants as well as anti-caries vaccine and anti-RSV vaccine. His research is mostly funded by National Natural Science Foundation of China, the Ministry of Science and Technology of China.

李亚霏博士毕业于香港大学医学院，南山领航人才，主要从事纳米制剂的研发与工艺开发，在Cell Discovery、Small、Nano Research等国际知名学术期刊上发表论文6篇，申请相关专利10余个。现就职于瑞吉生物，担任研发总监，负责了多个管线的制剂开发，主导搭建了mRNA-LNP冻干工艺平台，完成首个国内获得IND批件的冻干mRNA-LNP工艺开发。

Christopher Gill has an MD from the University of Massachusetts Medical School and an MS from the Tufts School of Graduate Biomedical Studies.  Dr. Gill is an infectious disease specialist by training. From 2002-2008 and again from 2011-2023 he was a faculty member of the Department of Global Health at Boston University School of Public Health rising eventually to the level of full professor of Global Health.  During the intervening years 2008-11 he was the clinical director for the development of the MenACWY-CRM conjugate meningitis vaccine for Novartis Vaccines and Diagnostics. His work has centered broadly on child-survival in the areas of diarrheal diseases, pneumonia, and neonatal survival. However, his largest concentration of work has focused on better understanding the epidemiology of pediatric respiratory infections, notably Streptococcus pneumoniae, Bordetella pertussis and Respiratory Syncytial Virus.  At BU, Dr. Gill was the 2015 recipient of the Norman Scotch Award for excellence in teaching at Boston University School of Public Health, and the 2016 recipient of Boston University's Metcalf Cup and Prize. The Metcalf Cup and Prize is BU's highest teaching honor and is awarded to one of BU's >3500 faculty across its 17 colleges and schools each year.  At the Gates Foundation, Dr. Gill’s main areas are development of combination vaccines and expanding the impact of HPV vaccination globally. 

Markus is Head of Analytical Development, Microbiology, and Quality Control for the MAP-Program at LTS Lohmann Therapie Systeme AG in Andernach. He studied biology at Philipps University in Marburg, Germany, and was awarded a PhD in Parasitology in 2009 for his work on the membrane physiology and biochemistry of the Malaria parasite. From 2009 to 2015 he expanded his track record in infectious disease research at The Australian National University in Canberra, Australia. In 2015, he accepted a position for the University of Oxford, leading the Clinical Pharmacology laboratories at the Mahidol-Oxford Tropical Medicine Research Unit in Bangkok, Thailand. In 2019 he joined LTS as Head of Analytical Development, Microbiology and Quality Control for the MAP Program.

博士毕业于美国弗吉尼亚州的欧道明大学，主攻方向为Vector-Borne disease中黄热病毒属（LGTV，ZIKV， DENV等病毒）依靠外泌体进行体内体外感染传播的机理研究并将成果发表在多个高影响因子杂志上（PNAS， EMI， PLoS Pathogen等）。

后在美国食品药品监督管理局FDA，CBER下设的疫苗评审研究办公室OVRR担任白橡树外国科学家项目博士后研究员（ORISE Fellow）从事以减毒风疹病毒为载体对新冠S蛋白，RSV或HIV相关蛋白表达的重组载体疫苗的研发工作。

目前在国药中生集团旗下的子公司中生复诺健生物科技有限公司担任资深科学家和学术秘书，负责多条传染病mRNA疫苗管线的早期研发和相关学术会议组织和讨论工作。

Juhienah Khalaf is a medicinal chemist with expertise in the synthesis and development of bioactive compounds, including antifungal agents, immunomodulators, and protease inhibitors. With a strong background in organic and combinatorial chemistry, Juhienah has contributed to advancing research in therapeutic molecules targeting immune responses and infectious diseases. Her work spans the design and synthesis of TLR4 agonists, small-molecule drugs, and immuno-based therapeutics. Juhienah's research has been instrumental in the development of novel adjuvant systems and targeted therapies, aiming to address critical challenges in immunology and infectious disease treatment.  Juhienah first synthesized INI-2002, a TLR4 agonist that has become the lead component in Inimmune's Adjuvant Systems. This work is presented at the Vaccine Industry Forum (VIF) conference, highlighting its potential in enhancing vaccine efficacy through targeted immune modulation.

Yongming Chen received his Master degree of chemistry in 1990 from Northwest University, Xian. In 1993, he obtained his Ph.D. on polymer science from Nankai University, Tianjin. From 1994 to 1998, he was Postdoctoral Researcher and later Research Assistant at the Institute of Chemistry, CAS. Then he spent the period 1998−2001 as Postdoctoral Researcher in the University of Düsseldorf and the University of Mainz. Since 2001, Chen was Professor at the Institute of Chemistry CAS. He moved to Sun Yat-sen University in 2013 and he works in Henan University in 2024. He obtained the “Distinguished Young Scholars” by the National Science Foundation of China (2006) and the “Wang Bo-Ren Polymer Research Award” by the Chinese Chemistry Society (2011). He served for Polymer, an Elsevier journal as an Associate Editor from 2007 to 2018. He also was on the Advisory Board Panel of Macromolecules and ACS Macro Letters. Professor Chen’s research interests are in the areas of synthesis methodology of polymers and polymer application in nanomedicine on biologics delivery, immune activation and inhibition. He has published over 300 research articles and around 30 patents approved.

Dr Sandy Douglas is a principal investigator and academic clinician. He led the development of the large-scale manufacturing process for the Oxford-AstraZeneca COVID-19 vaccine, which has resulted in over 2 billion doses being manufactured by late 2021. Sandy is Chief Investigator of the COV008 phase I clinical trial of intranasal administration of this vaccine. He holds a Wellcome Trust Clinical Research Career Development Fellowship, is a Co-Investigator on the EPSRC funded Future Vaccine Manufacturing Research Hub (Vax-Hub) and holds an MRC grant to develop a novel rabies vaccine and carry out clinical trials.

-17年疫苗临床行业经验 n前广西疾控疫苗临床研究所所长（2010-2022），管理和实施过近300个临床试验，70+个疫苗临床试验PI，多个大型疫苗多中心效力试验leading PI。 

-CDE药审专家和国家专班专家，曾参与编著和讨论多个国家疫苗临床试验相关法规、技术指导原则，多次参加重大新药创制科技重大专项课题。 n曾作为PI主持：全球首个人二倍体细胞EV71灭活疫苗、国内首个mRNA新冠疫苗、HPV疫苗、轮状病毒疫苗、微卡、狂犬疫苗、IPV、bOPV、流感、肺炎疫苗、流脑疫苗等。 

-在国际期刊发表30+篇SCI论著，疫苗学第七版翻译编委、预防性疫苗临床试验设计与实施编委。 

-曾任国家局药品注册审评专家委员会委员、国务院联防联控机制科研攻关组疫苗研发专班专家组成员、国家免疫规划技术工作组成员、中华预防医学会疫苗临床专业委员会常委、原国家级和省级GCP检查员。

35年行业经验 

曾任中、美、欧药企高管，包括Amador，Worg，Alexion（AstraZeneca），Shire (Takeda)，CancerVax (Amgen) 及Elan (Perrigo) 

长期从事质量法规、医学临床，兼甲方乙方工作经验 

前FDA/CBER 评审

Dr. Hu Dong is an associate professor at Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences (CAAS). Focus on optimizing the assembly and stability of FMD virus-like particle antigen based on the structure of FMD virus, combined with the research on the immune mechanism of FMD cells, to further improve the protective efficacy of FMD virus-like particle vaccine or nanoparticle vaccine, and develop a broad-spectrum vaccine. At present, he has obtained 3 new veterinary drug certificates, and related researches have been published in Nature Communications, Journal of Virology, Protein and Cell.

陆汉新博士获乔治华盛顿大学遗传学博士学位，在生物医药产品开发领域拥有16年开拓性经验。他领导多学科团队推动治疗性与预防性疫苗技术平台创新，其开创性工作涵盖两大方向：开发针对高胆固醇血症等代谢紊乱及神经退行性病变的免疫治疗疫苗；设计新一代疫苗以应对呼吸道合胞病毒（RSV）、大流行流感、埃博拉病毒等新发传染性病原体。

陆博士的科学领导力贯穿疫苗研发全链条：从发现阶段的靶点验证、理性抗原设计及佐剂优化，到临床前开发的动物模型开发、机制研究与药效学分析，到生物标志物分层指导的I-III期临床试验，以及病毒学特性表征及符合GLP规范的疗效/安全性评估。

Christopher Obwanga is currently the East Africa Regional Manager at P95 Africa, bringing over 15 years of experience in clinical trials within the EMEA region, with a particular focus on sub-Saharan Africa.  Throughout his career, Christopher has held multiple roles including leadership positions at IQVIA and Roche.  

Kaiyao Wei earned his bachelor's degree from China Pharmaceutical University and completed his master's and Ph.D. at Université Grenoble Alpes, France, specializing in Virology, Microbiology, and Immunology.

During his doctoral research, he focused on validating novel drug targets for anti-infective therapies, with expertise in high-throughput screening optimization and structural biology studies.

Since transitioning into the pharmaceutical industry, Dr. Wei has contributed to the early-stage development of six mRNA vaccines and therapeutics, including RSV (IND approved by the FDA), influenza, and acne vaccines. Currently, he is engaged in quality research and control for RNA-based therapeutics and delivery systems, with comprehensive experience spanning R&D to manufacturing quality management.

His professional focus includes analytical method development, lifecycle management, and product quality control, ensuring robust and regulatory-compliant analytical strategies.

薛永博 博士

美国内华达大学细胞与分子生物学博士。

拥有超过10年以上的研发经验和5年以上的产业化经验，专注于生物技术领域的前沿创新与应用，致力于将科学研究转化为实际解决方案。 

在mRNA/环状RNA（circRNA）构建、基因编辑（如CRISPR/Cas9技术）及干细胞治疗领域具有丰富的研究与实践经验，主导并参与了多项突破性项目。 

作为核心研究人员，已成功发表超过10篇高水平学术论文，研究成果发表于国际知名期刊，展现了卓越的科研能力与学术影响力。

王娜，毕业于中国农业大学，任职厦门福流生物科技有限公司应用工程师，负责单分子纳米流式检测技术相关应用开发和售前技术支持工作，在新型疫苗递送方面具有扎实的理论基础和丰富的表征经验。

Dr. Qiu has 20 years of experience in pharmaceutical development and alliance management.

Joining WuXi Vaccines in 2021, she is the Head of Alliance Management in charge of collaborating with global partners, establishing and expanding relationship with international organizations, and driving the global health initiatives.

Before joining WuXi Vaccines, she was the project leader in Schering Plough Research Institute and Novartis Pharmaceutical Corp. in US. In 2014, she joined WuXi AppTec as Director of Alliance Management and Program Management, managing key collaborations with MNCs and developed program strategy for its first ADC project. Later she established the proposal team in WuXi Biologics, which facilitated its rapid expansion in late stage and commercial business development. 

Dr. Liu Yuanqing graduated from Shanghai Medical College of Fudan University and was a surgeon at Shanghai Zhongshan Hospital. He completed his PhD in Vrije Universiteit Brussel in Belgium and was one of the pioneers on myeloid-derived suppressors in tumors. He was previously a senior research lead at Sanofi Pasteur French headquarter, where he contributed to various vaccine projects, including cancer vaccines, vaccines against infectious diseases, pediatric vaccines, adjuvants, etc. Dr. Liu is an industry veteran with extensive experience in the development of innovative vaccines for international market. He was a member of the EU Innovative Medicine Initiative. Since 2021, he has been the Chief Scientific Officer of Immorna Biotechnology. He is based in Shanghai where Immorna has established a high-standard R&D site aiming to accelerate the development of mRNA vaccines and drugs in China.

Andrew Wong is a highly experienced professional with a strong background in biotech, vaccine development, and business management. Currently serving as the Senior Advisor to the Board of Directors at Walvax, Andrew has made significant contributions to the company's global operations.

Before taking on this advisory role, he was the General Manager of Shanghai Wotai Biotechnology Co., Ltd. from 2019, where he led a global team of over 50 professionals. His team was responsible for global vaccine registration, sales, marketing, technology transfer, and business development. Under his leadership, the team became one of China's leading vaccine export groups, expanding into 21 foreign markets such as Egypt, Morocco, Indonesia, and Thailand. His efforts led to a remarkable 25% compound annual growth rate in vaccine exports over the past five years.

Andrew's tenure at Walvax also includes an eight-year stint as Vice President of Corporate Strategy and Business Development at Shanghai Zerun Biotechnology Co., Ltd. From 2015 to 2020, he played a crucial role in securing major research and development grants, including a $7.5 million funding from the Bill and Melinda Gates Foundation for the development of HPV vaccines. Additionally, he was instrumental in securing R&D grants for Covid-19 vaccines, totaling $26 million from the Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI).

Andrew's academic background includes training in medicine and immunology (MSc) at West China Medical University (now Sichuan University), molecular biology (MSc) at the University of Manitoba, and an MBA from UCLA Anderson School of Management. His 30-year career includes about 12 years of experience at Amgen Inc., where he contributed to the development of recombinant antibody therapeutics and anticancer drugs. With his extensive experience in biotech, vaccine research, and global business development, Andrew Wong has been a driving force in Walvax’s global expansion and success in the vaccine market.

胡颖

昭衍（苏州）新药研究中心有限公司，毒理二部主任

中国认证毒理学家（DCST），中国毒理学会生殖毒理专业委员会青年委员。本科和研究生曾就读于扬州大学兽医学院，硕士学位。从事药物毒理安全性评价工作14+，作为专题负责人完成550+项非临床毒理学研究，包括一般毒理、生殖和发育毒理、幼龄动物毒理试验、致癌性试验等。主要业务方向包括小分子化药、单克隆抗体/双特异性抗体、融合蛋白、多肽、疫苗、小核酸药物等。

He has been engaged in the development of carbohydrate compounds, excipients and adjuvants.

Dr. Jeff Zhu is the founder and CEO of Shanghai Reinovax Biologics co., Ltd., a fast-growing biotech company focusing on discovery and development of innovative vaccines and other biologics. Dr. Zhu has over 20 years’ industrial experience on discovery and development of small molecules, recombinant proteins, antibodies and vaccines from the early discovery to clinical trials. He played an important role in moving multiple drug candidates from the initiation to the clinical trial stage during his 13-year tenure at Pfizer’s R & D center in San Diego. Dr. Zhu moved back to China in 2011, and served as CSO and head of the R & D at Hualan Biological Engineering Inc., and two years later worked as senior director and department head in USP, Shanghai. Dr. Zhu published earned his Ph.D. degree on biological sciences from UC, Irvine, M.S. degree on biochemistry from Georgetown university, and B.S. degree on chemistry from Tsinghua university.